North America in vitro diagnostics Market Share Analysis Report, 2023-2032
The North America in vitro diagnostics market size was exhibited at USD 50.19 billion in 2022 and is projected to hit around USD 66.86 billion by 2032, growing at a CAGR of 2.91% during the forecast period 2023 to 2032.
Key Pointers:
North America in vitro diagnostics Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 51.65 Billion |
|
Market Size by 2032 |
USD 66.86 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 2.91% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Product, Technology, Application, End-use, Test location, Region |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Key companies profiled |
Abbott; bioMérieux SA; Bio-Rad Laboratories, Inc.; BD; Siemens Healthcare GmbH; QIAGEN; Quidel Corporation; F. Hoffmann-La Roche Ltd; Sysmex Corporation; Charles Rivers Laboratories International, Inc.; Quest Diagnostics; Danaher |
The market is also expected to cater to various growth opportunities in key segments. For example, the development of automated in vitro diagnostic solutions for hospitals and laboratories to provide accurate, efficient, and error-free diagnosis is anticipated to drive market growth in the coming years. In addition, rising efforts to develop POC solutions and the surge in adoption of POC tests across different medical diagnostic applications, including infectious diseases, pregnancy, cancer, and others, are fueling the market growth.
The market growth is likely to be fueled by rising efforts from leading participants to develop fast and accurate products that allow easy-to-use, advanced, and flexible testing options. For instance, in August 2022, DxGen Corp. and Precision Diabetes, Inc. announced an agreement to develop and launch a fully automatic POC analyzer in the U.S. market to measure a complete profile of diabetes tests. The analyzer is capable to test C-reactive protein, urine analysis, A1C levels, and other diabetes confirmatory tests at POC facilities.
Furthermore, in November 2021, Lumos Diagnostics, a key player in POC diagnostics, announced that its Lumos CoviDx SARS-CoV-2 Rapid Antigen Test received an interim order authorization from Health Canada. This test offers easy-to-interpret outcomes in just 15-20 minutes in serial testing of asymptomatic patients. The easy availability of point-of-care tests in home care settings, community pharmacies, retail health clinics, urgent care centers, intensive care units, and operating rooms is fueling the adoption of POC IVD products across the region.
The North America in vitro diagnostics industry is gaining traction as diagnostic laboratories frequently employ fully automated tools. Moreover, automated devices are highly scalable, meet a high level of performance expectations, eliminate batch testing, and provide quick results to medical professionals. Leading participants are continuously working on building automated devices because of these benefits. For instance, in May 2022, BD launched a new, fully automated high-throughput infectious disease molecular diagnostics platform in the U.S. market.
Furthermore, the increasing incidence of target diseases, favorable government initiatives, and the flourishing healthcare sector in the region are anticipated to offer lucrative growth opportunities.
For instance, in November 2022, Hologic, Inc. was awarded a USD 19 million contract from BARDA to support its research and development activities. In addition, in January 2022, Aline, Inc. & Nectar Product Development announced a strategic partnership to improve POC in vitro diagnostic products.
Product Insights
The reagents segment held the largest share of 65.9% in 2022 and is anticipated to advance at a steady CAGR during the projected period. Factors such as extensive R&D initiatives being undertaken by major market players for the development of novel tests for different applications and the commercialization of new reagents are likely to drive market growth.
For instance, in March 2021, Promega Corporation introduced XpressAmp direct amplification reagents, which facilitate automation-friendly RNA extraction-free sample preparation. Moreover, in November 2021, 28 Fungal Analyte Specific Reagents (ASRs) were launched by Applied BioCode to sell to clinical laboratories and IVD manufacturers.
The instruments segment held the second largest revenue share in 2022; the high revenue share of the segment can be attributed to the rising demand for PoC testing instruments, technological advancements, and the rising demand for advanced instruments by end-users. Furthermore, key manufacturers are focused on developing new technologies with higher efficiency & accuracy. For instance, the VIDAS and MINI VIDAS systems by bioMérieux are multiparametric immunoassay systems designed to offer highly accurate & precise laboratory results.
Technology Insights
The molecular diagnostics segment dominated the market for North America in vitro diagnostics owing to factors such as rapid evolution in technology, increasing burden of target diseases, the outbreak of COVID-19, and surge in product launches by leading participants. For instance, in November 2022, Roche planned to launch the cobas 5800 system, a compact and fully automated lab instrument that offers flexible PCR testing solutions, in the U.S.
Moreover, the presence of flexible regulations for manufacturers to combat the rising number of infectious diseases is anticipated to accelerate North America in vitro diagnostics industry growth. For instance, in March 2021, the U.S. FDA issued a EUA for Abbott’s molecular test to detect COVID-19. Moreover, the launch of initiatives & programs is further propelling the demand for molecular diagnostics to reduce disease burden. For instance, in March 2022, Molecular Characterization Initiative was launched by the National Cancer Institute to provide childhood cancer molecular characterization.
The rising demand for regular health checkups, the surge in the prevalence of hematological disorders, and the rising demand for POC & portable devices are some factors responsible for the growth of the hematology segment. The rising demand for benchtop and portable devices is pushing manufacturers to develop hematology instruments with new features and enhanced performance. For instance, in July 2022, HORIBA Medical launched Yumizen 550 and 500 in its hematology product portfolio. Similarly, in August 2020, IDEXX Laboratories, Inc. launched the ProCyte One Hematology Analyzer, which delivers accurate and consistent results with operability in PoC settings.
Application Insights
In 2022, the infectious disease segment held the largest market share of 60.8% owing to the rising burden of infectious diseases in the region and the increasing uptake of IVD products for the detection of infectious diseases. The COVID-19 pandemic has increased segment growth exponentially. In addition, leading participants are engaged in commercializing precise testing solutions for infectious diseases. For instance, in October 2021, QIAGEN launched the QuantiFERON-TB test for tuberculosis infection. The newly launched product aimed to reduce the rising tuberculosis burden in the region.
The diabetes segment held the second largest share due to the growing trend of a sedentary lifestyle in North America, the prevalence of obesity, and the rising demand for homecare diagnostic solutions. Several companies are introducing portable and home-use devices owing to their high demand. For instance, in May 2022, LabCorp launched the LabCorp OnDemand at-home collection kit, which can measure HbA1c from small blood samples.
The oncology segment is anticipated to exhibit a lucrative growth rate throughout the forecast period. The increasing burden of cancer in the U.S. & Canada, rising demand for advanced screening solutions, and increasing awareness for early disease diagnosis among people are all expected to support segment expansion.
Test Location Insights
Most tests are performed in central laboratory settings. However, the increased focus of the regulatory bodies on self-test or OTC molecular diagnostics to lower the burden on laboratories is boosting the OTC test market’s growth. For instance, in March 2021, Cue Health, Inc. announced the U.S. FDA approval of its OTC and at-home self-test for SARS-CoV-2, making it the first non-prescription diagnostic test in the U.S. Moreover, in May 2021, the retail chain Kroger Co. announced the availability of self-testing kits by Abbott across its store to increase overall access to test kits.
The point-of-care segment is projected to register a robust growth rate throughout the projected period. The rising developments of tests that provide faster detection are projected to boost the segment’s growth. These POC tests have revolutionized the market by decreasing the processing time and augmenting rapid decision-making. For instance, in April 2021, the U.S. FDA approved amended EUA requests for various tests, expanding POC and OTC testing options for COVID-19.
End-use Insights
The hospitals segment captured the largest revenue share in 2022. Factors such as the rising demand for affordable services, increasing hospitalization rates, the surging trend of personalized treatments, and the presence of favorable reimbursement policies are fueling the segment’s expansion. Moreover, the increasing incidence of hospital-acquired infections in hospitalized patients is expected to support market growth. According to the CDC, around 5% of hospitalized patients suffer from MRSA infections and carry the bacteria.
On the other hand, home care is likely to show a positive growth rate during the coming years. The rising demand for homecare in vitro diagnostic devices, the surge in the geriatric population, and the robust availability of portable home-use IVD products are facilitating segment expansion. Moreover, favorable government initiatives to promote home care diagnosis are fueling segment growth. For instance, the U.S. FDA has authorized a large number of over-the-counter COVID-19 diagnostic tests for home use.
Regional Insights
The U.S. led the North America in vitro diagnostics industry in 2022 due to the presence of many strong players coupled with various strategic initiatives undertaken by them. Moreover, the high burden of target diseases, rising demand for advanced diagnostic solutions at different healthcare facilities, and surge in demand for POC tests are also anticipated to support the growth.
Canada is projected to witness the fastest growth rate over the forecast period. The increasing geriatric population, large patient pool with the increasing prevalence of chronic diseases, and supportive reimbursement policies in the country are the factors bolstering the country’s market growth. Moreover, the introduction of technologically advanced products is likely to cater to the nation's market. For instance, in October 2021, Bio-Rad introduced the CFX Opus 384 Dx System and CFX Opus 96 Dx Systems, which are real-time PCR detection systems.
Some of the prominent players in the North America in vitro diagnostics Market include:
Segments Covered in the Report
This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global North America in vitro diagnostics market.
By Product
By Technology
By Application
By End-use
By Test Location
By Regional
Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 North America Ivd Market Variables, Trends, & Scope
3.1 Ivd Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Market Driver Analysis
3.3.1 Growing Geriatric Population
3.3.2 Technological Advancements
3.3.3 Increasing Demand For Poc Facilities
3.3.4 Growing Prevalence Of Target Diseases Such As Genetic, Cardiovascular, & Neurological Diseases And Hospital-Acquired Infections
3.3.5 Outbreak Of Covid-19
3.4 Market Restraint Analysis
3.4.1 High Cost Of Devices
3.4.2 Stringent Regulatory Policies
3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
3.6 Porter’s Five Forces Analysis
3.7 Pipeline Analysis, By Phase
3.8 Regulatory & Reimbursement Scenario
3.9 Pricing Analysis
Chapter 4 North America Ivd Market–Segment Analysis, By Product, 2020 - 2032 (Volume, Number Of Tests And Instruments; Revenue, USD Million, 2020 - 2032)
4.1 North America In Vitro Diagnostic Market: Products Movement Analysis
4.2 Instruments
4.2.1 Instruments Market Estimates And Forecast, 2020 - 2032
4.2.2 Hospitals
4.2.2.1 Hospitals Market Estimates And Forecast, 2020 - 2032
4.2.3 Laboratories
4.2.3.1 Laboratories Market Estimates And Forecast, 2020 - 2032
4.2.4 Home Care
4.2.4.1 Home Care Market Estimates And Forecast, 2020 - 2032
4.2.5 Clinic
4.2.5.1 Clinic Market Estimates And Forecast, 2020 - 2032
4.2.5.2 Physician Office
4.2.5.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
4.2.5.3 Pharmacy & Retail Clinics
4.2.5.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
4.2.5.4 Non-Practice Clinics
4.2.5.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
4.2.5.5 Urgent Care Clinics
4.2.5.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
4.2.5.6 Others
4.2.5.6.1 Others Market Estimates And Forecast, 2020 - 2032
4.3 Reagents
4.3.1 Reagents Market Estimates And Forecast, 2020 - 2032
4.3.2 Hospitals
4.3.2.1 Hospitals Market Estimates And Forecast, 2020 - 2032
4.3.3 Laboratories
4.3.3.1 Laboratories Market Estimates And Forecast, 2020 - 2032
4.3.4 Home Care
4.3.4.1 Home Care Market Estimates And Forecast, 2020 - 2032
4.3.5 Clinic
4.3.5.1 Clinic Market Estimates And Forecast, 2020 - 2032
4.3.5.2 Physician Office
4.3.5.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
4.3.5.3 Pharmacy & Retail Clinics
4.3.5.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
4.3.5.4 Non-Practice Clinics
4.3.5.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
4.3.5.5 Urgent Care Clinics
4.3.5.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
4.3.5.6 Others
4.3.5.6.1 Others Market Estimates And Forecast, 2020 - 2032
4.4 Services
4.4.1 Services Market Estimates And Forecast, 2020 - 2032
4.4.2 Hospitals
4.4.2.1 Hospitals Market Estimates And Forecast, 2020 - 2032
4.4.3 Laboratories
4.4.3.1 Laboratories Market Estimates And Forecast, 2020 - 2032
4.4.4 Home Care
4.4.4.1 Home Care Market Estimates And Forecast, 2020 - 2032
4.4.5 Clinic
4.4.5.1 Clinic Market Estimates And Forecast, 2020 - 2032
4.4.5.2 Physician Office
4.4.5.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
4.4.5.3 Pharmacy & Retail Clinics
4.4.5.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
4.4.5.4 Non-Practice Clinics
4.4.5.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
4.4.5.5 Urgent Care Clinics
4.4.5.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
4.4.5.6 Others
4.4.5.6.1 Others Market Estimates And Forecast, 2020 - 2032
Chapter 5 North America Ivd Market–Segment Analysis, By Technology, 2020 - 2032 (Revenue, USD Million) (Volume, Number Of Test And Instruments)
5.1 North America In Vitro Diagnostics Market: Technology Movement Analysis
5.2 Immunoassay
5.2.1 Immunoassay Market Estimates And Forecast, 2020 - 2032
5.2.2 Products
5.2.2.1 Instruments
5.2.2.1.1 Instruments Market For Immunoassay Estimates And Forecast, 2020 - 2032
5.2.2.2 Reagents
5.2.2.2.1 Reagents Market For Immunoassay Estimates And Forecast, 2020 - 2032
5.2.2.3 Services
5.2.2.3.1 Services Market For Immunoassay Estimates And Forecast, 2020 - 2032
5.2.3 End-Use
5.2.3.1 Hospitals
5.2.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
5.2.3.2 Laboratories
5.2.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
5.2.3.3 Home Care
5.2.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
5.2.3.4 Clinic
5.2.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
5.2.3.4.2 Physician Office
5.2.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
5.2.3.4.3 Pharmacy & Retail Clinics
5.2.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
5.2.3.4.4 Non-Practice Clinics
5.2.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
5.2.3.4.5 Urgent Care Clinics
5.2.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
5.2.3.4.6 Others
5.2.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
5.3 Hematology
5.3.1 Hematology Market Estimates And Forecast, 2020 - 2032
5.3.2 Products
5.3.2.1 Instruments
5.3.2.1.1 Instruments Market For Hematology Estimates And Forecast, 2020 - 2032
5.3.2.2 Reagents
5.3.2.2.1 Reagents Market For Hematology Estimates And Forecast, 2020 - 2032
5.3.2.3 Services
5.3.2.3.1 Services Market For Hematology Estimates And Forecast, 2020 - 2032
5.3.3 End-Use
5.3.3.1 Hospitals
5.3.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
5.3.3.2 Laboratories
5.3.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
5.3.3.3 Home Care
5.3.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
5.3.3.4 Clinic
5.3.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
5.3.3.4.2 Physician Office
5.3.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
5.3.3.4.3 Pharmacy & Retail Clinics
5.3.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
5.3.3.4.4 Non-Practice Clinics
5.3.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
5.3.3.4.5 Urgent Care Clinics
5.3.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
5.3.3.4.6 Others
5.3.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
5.4 Clinical Chemistry
5.4.1 Clinical Chemistry Market Estimates And Forecast, 2020 - 2032
5.4.2 Products
5.4.2.1 Instruments
5.4.2.1.1 Instruments Market For Clinical Chemistry Estimates And Forecast, 2020 - 2032
5.4.2.2 Reagents
5.4.2.2.1 Reagents Market For Clinical Chemistry Estimates And Forecast, 2020 - 2032
5.4.2.3 Services
5.4.2.3.1 Services Market For Clinical Chemistry Estimates And Forecast, 2020 - 2032
5.4.3 End-Use
5.4.3.1 Hospitals
5.4.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
5.4.3.2 Laboratories
5.4.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
5.4.3.3 Home Care
5.4.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
5.4.3.4 Clinic
5.4.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
5.4.3.4.2 Physician Office
5.4.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
5.4.3.4.3 Pharmacy & Retail Clinics
5.4.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
5.4.3.4.4 Non-Practice Clinics
5.4.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
5.4.3.4.5 Urgent Care Clinics
5.4.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
5.4.3.4.6 Others
5.4.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
5.5 Molecular Diagnostics
5.5.1 Molecular Diagnostics Market Estimates And Forecast, 2020 - 2032
5.5.2 Products
5.5.2.1 Instruments
5.5.2.1.1 Instruments Market For Molecular Diagnostics Estimates And Forecast, 2020 - 2032
5.5.2.2 Reagents
5.5.2.2.1 Reagents Market For Molecular Diagnostics Estimates And Forecast, 2020 - 2032
5.5.2.3 Services
5.5.2.3.1 Services Market For Molecular Diagnostics Estimates And Forecast, 2020 - 2032
5.5.3 End-Use
5.5.3.1 Hospitals
5.5.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
5.5.3.2 Laboratories
5.5.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
5.5.3.3 Home Care
5.5.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
5.5.3.4 Clinic
5.5.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
5.5.3.4.2 Physician Office
5.5.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
5.5.3.4.3 Pharmacy & Retail Clinics
5.5.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
5.5.3.4.4 Non-Practice Clinics
5.5.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
5.5.3.4.5 Urgent Care Clinics
5.5.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
5.5.3.4.6 Others
5.5.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
5.6 Coagulation
5.6.1 Coagulation Market Estimates And Forecast, 2020 - 2032
5.6.2 Products
5.6.2.1 Instruments
5.6.2.1.1 Instruments Market For Coagulation Estimates And Forecast, 2020 - 2032
5.6.2.2 Reagents
5.6.2.2.1 Reagents Market For Coagulation Estimates And Forecast, 2020 - 2032
5.6.2.3 Services
5.6.2.3.1 Services Market For Coagulation Estimates And Forecast, 2020 - 2032
5.6.3 End-Use
5.6.3.1 Hospitals
5.6.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
5.6.3.2 Laboratories
5.6.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
5.6.3.3 Home Care
5.6.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
5.6.3.4 Clinic
5.6.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
5.6.3.4.2 Physician Office
5.6.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
5.6.3.4.3 Pharmacy & Retail Clinics
5.6.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
5.6.3.4.4 Non-Practice Clinics
5.6.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
5.6.3.4.5 Urgent Care Clinics
5.6.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
5.6.3.4.6 Others
5.6.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
5.7 Microbiology
5.7.1 Microbiology Market Estimates And Forecast, 2020 - 2032
5.7.2 Products
5.7.2.1 Instruments
5.7.2.1.1 Instruments Market For Microbiology Estimates And Forecast, 2020 - 2032
5.7.2.2 Reagents
5.7.2.2.1 Reagents Market For Microbiology Estimates And Forecast, 2020 - 2032
5.7.2.3 Services
5.7.2.3.1 Services Market For Microbiology Estimates And Forecast, 2020 - 2032
5.7.3 End-Use
5.7.3.1 Hospitals
5.7.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
5.7.3.2 Laboratories
5.7.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
5.7.3.3 Home Care
5.7.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
5.7.3.4 Clinic
5.7.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
5.7.3.4.2 Physician Office
5.7.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
5.7.3.4.3 Pharmacy & Retail Clinics
5.7.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
5.7.3.4.4 Non-Practice Clinics
5.7.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
5.7.3.4.5 Urgent Care Clinics
5.7.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
5.7.3.4.6 Others
5.7.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
5.8 Others
5.8.1 Others Market Estimates And Forecast, 2020 - 2032
5.8.2 Instruments
5.8.2.1 Instruments Market Estimates And Forecast, 2020 - 2032
5.8.3 Reagents
5.8.3.1 Reagents Market Estimates And Forecast, 2020 - 2032
5.8.4 Services
5.8.4.1 Services Market Estimates And Forecast, 2020 - 2032
Chapter 6 North America Ivd Market: Segment Analysis, By Application, 2020 - 2032
6.1 North America In Vitro Diagnostics Market: Application Movement Analysis
6.2 Infectious Diseases
6.2.1 Infectious Diseases Market Estimates And Forecast, 2020 - 2032
6.2.2 Disease
6.2.2.1. Methicillin-Resistant Staphylococcus Aureus (Mrsa)
6.2.2.1.1 Methicillin-Resistant Staphylococcus Aureus (Mrsa) Market Estimates And Forecast, 2020 - 2032
6.2.2.1.2 Clostridium Difficile
6.2.2.1.2.1 Clostridium Difficile Market Estimates And Forecast, 2020 - 2032
6.2.2.1.3 Vancomycin-Resistant Enterococci (Vre)
6.2.2.1.3.1 Vancomycin-Resistant Enterococci (Vre) Market Estimates And Forecast, 2020 - 2032
6.2.2.1.4 Carbapenem-Resistant Bacteria
6.2.2.1.4.1 Carbapenem-Resistant Bacteria Market Estimates And Forecast, 2020 - 2032
6.2.2.1.5 Flu
6.2.2.1.5.1 Flu Market Estimates And Forecast, 2020 - 2032
6.2.2.1.6 Respiratory Syncytial Virus (Rsv)
6.2.2.1.6.1 Respiratory Syncytial Virus (Rsv) Market Estimates And Forecast, 2020 - 2032
6.2.2.1.7 Candida
6.2.2.1.7.1 Candida Market Estimates And Forecast, 2020 - 2032
6.2.2.1.8 Tuberculosis And Drug-Resistant Tb
6.2.2.1.8.1 Tuberculosis And Drug-Resistant Tb Market Estimates And Forecast, 2020 - 2032
6.2.2.1.9 Meningitis
6.2.2.1.9.1 Meningitis Market Estimates And Forecast, 2020 - 2032
6.2.2.1.10 Gastrointestinal Panel Testing
6.2.2.1.10.1 Gastrointestinal Panel Testing Market Estimates And Forecast, 2020 - 2032
6.2.2.1.11 Chlamydia
6.2.2.1.11.1 Chlamydia Market Estimates And Forecast, 2020 - 2032
6.2.2.1.12 Gonorrhea
6.2.2.1.12.1 Gonorrhea Market Estimates And Forecast, 2020 - 2032
6.2.2.1.13 Hiv
6.2.2.1.13.1 Hiv Market Estimates And Forecast, 2020 - 2032
6.2.2.1.14 Hepatitis C
6.2.2.1.14.1 Hepatitis C Market Estimates And Forecast, 2020 - 2032
6.2.2.1.15 Hepatitis B
6.2.2.1.15.1 Hepatitis B Market Estimates And Forecast, 2020 - 2032
6.2.2.1.16 Other Infectious Disease
6.2.2.1.16.1 Other Infectious Disease Market Estimates And Forecast, 2020 - 2032
6.2.3 End-Use
6.2.3.1 Hospitals
6.2.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.2.3.2 Laboratories
6.2.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.2.3.3 Home Care
6.2.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.2.3.4 Clinic
6.2.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.2.3.4.2 Physician Office
6.2.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.2.3.4.3 Pharmacy & Retail Clinics
6.2.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.2.3.4.4 Non-Practice Clinics
6.2.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.2.3.4.5 Urgent Care Clinics
6.2.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.2.3.4.6 Others
6.2.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.3 Diabetes
6.3.1 Diabetes Market Estimates And Forecast, 2020 - 2032
6.3.2 End-Use
6.3.2.1 Hospitals
6.3.2.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.3.2.2 Laboratories
6.3.2.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.3.2.3 Home Care
6.3.2.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.3.2.4 Clinic
6.3.2.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.3.2.4.2 Physician Office
6.3.2.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.3.2.4.3 Pharmacy & Retail Clinics
6.3.2.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.3.2.4.4 Non-Practice Clinics
6.3.2.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.3.2.4.5 Urgent Care Clinics
6.3.2.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.3.2.4.6 Others
6.3.2.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.4 Oncology
6.4.1 Oncology Market Estimates And Forecast, 2020 - 2032
6.4.2 Disease
6.4.2.1.Breast Cancer
6.4.2.1.1 Breast Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.2 Prostate Cancer
6.4.2.1.2.1 Prostate Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.3 Colorectal Cancer
6.4.2.1.3.1 Colorectal Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.4 Cervical Cancer
6.4.2.1.4.1 Cervical Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.5 Kidney Cancer
6.4.2.1.5.1 Kidney Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.6 Liver Cancer
6.4.2.1.6.1 Liver Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.7 Blood Cancer
6.4.2.1.7.1 Blood Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.8 Lung Cancer
6.4.2.1.8.1 Lung Cancer Market Estimates And Forecast, 2020 - 2032
6.4.2.1.9 Other Cancer
6.4.2.1.9.1 Other Cancer Market Estimates And Forecast, 2020 - 2032
6.4.3 End-Use
6.4.3.1 Hospitals
6.4.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.4.3.2 Laboratories
6.4.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.4.3.3 Home Care
6.4.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.4.3.4 Clinic
6.4.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.4.3.4.2 Physician Office
6.4.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.4.3.4.3 Pharmacy & Retail Clinics
6.4.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.4.3.4.4 Non-Practice Clinics
6.4.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.4.3.4.5 Urgent Care Clinics
6.4.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.4.3.4.6 Others
6.4.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.5 Cardiology
6.5.1 Cardiology Market Estimates And Forecast, 2020 - 2032
6.5.2 Disease
6.5.2.1. Coronary Heart Disease
6.5.2.1.1 Coronary Heart Disease Market Estimates And Forecast, 2020 - 2032
6.5.2.1.2 Stroke
6.5.2.1.2.1 Stroke Market Estimates And Forecast, 2020 - 2032
6.5.2.1.3 Peripheral Arterial Disease
6.5.2.1.3.1 Peripheral Arterial Disease Market Estimates And Forecast, 2020 - 2032
6.5.2.1.4 Aortic Disease
6.5.2.1.4.1 Aortic Disease Market Estimates And Forecast, 2020 - 2032
6.5.2.1.5 Others
6.5.2.1.5.1 Others Market Estimates And Forecast, 2020 - 2032
6.5.3 End-Use
6.5.3.1 Hospitals
6.5.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.5.3.2 Laboratories
6.5.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.5.3.3 Home Care
6.5.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.5.3.4 Clinic
6.5.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.5.3.4.2 Physician Office
6.5.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.5.3.4.3 Pharmacy & Retail Clinics
6.5.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.5.3.4.4 Non-Practice Clinics
6.5.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.5.3.4.5 Urgent Care Clinics
6.5.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.5.3.4.6 Others
6.5.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.6 Nephrology
6.6.1 Nephrology Market Estimates And Forecast, 2020 - 2032
6.6.2 Disease
6.6.2.1. Uti
6.6.2.1.1 Uti Market Estimates And Forecast, 2020 - 2032
6.6.2.1.2 Kidney Disease
6.6.2.1.2.1 Kidney Disease Market Estimates And Forecast, 2020 - 2032
6.6.2.1.3 Diabetes
6.6.2.1.3.1 Diabetes Market Estimates And Forecast, 2020 - 2032
6.6.2.1.4 Others
6.6.2.1.4.1 Others Market Estimates And Forecast, 2020 - 2032
6.6.3 End-Use
6.6.3.1 Hospitals
6.6.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.6.3.2 Laboratories
6.6.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.6.3.3 Home Care
6.6.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.6.3.4 Clinic
6.6.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.6.3.4.2 Physician Office
6.6.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.6.3.4.3 Pharmacy & Retail Clinics
6.6.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.6.3.4.4 Non-Practice Clinics
6.6.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.6.3.4.5 Urgent Care Clinics
6.6.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.6.3.4.6 Others
6.6.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.7 Autoimmune Diseases
6.7.1 Autoimmune Diseases Market Estimates And Forecast, 2020 - 2032
6.7.2 Disease
6.7.2.1. Rheumatoid Arthritis
6.7.2.1.1.1 Rheumatoid Arthritis Market Estimates And Forecast, 2020 - 2032
6.7.2.1.2 Inflammatory Bowel Disease
6.7.2.1.2.1 Inflammatory Bowel Disease Market Estimates And Forecast, 2020 - 2032
6.7.2.1.3 Osteoporosis
6.7.2.1.3.1 Osteoporosis Market Estimates And Forecast, 2020 - 2032
6.7.2.1.4 Celiac Disease
6.7.2.1.4.1 Celiac Disease Market Estimates And Forecast, 2020 - 2032
6.7.2.1.5 Fibromyalgia
6.7.2.1.5.1 Fibromyalgia Market Estimates And Forecast, 2020 - 2032
6.7.3 End-Use
6.7.3.1 Hospitals
6.7.3.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.7.3.2 Laboratories
6.7.3.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.7.3.3 Home Care
6.7.3.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.7.3.4 Clinic
6.7.3.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.7.3.4.2 Physician Office
6.7.3.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.7.3.4.3 Pharmacy & Retail Clinics
6.7.3.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.7.3.4.4 Non-Practice Clinics
6.7.3.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.7.3.4.5 Urgent Care Clinics
6.7.3.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.7.3.4.6 Others
6.7.3.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.8 Drug Testing
6.8.1 Drug Testing Market Estimates And Forecast, 2020 - 2032
6.8.2 End-Use
6.8.2.1 Hospitals
6.8.2.1.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.8.2.2 Laboratories
6.8.2.2.1 Laboratories Market Estimates And Forecast, 2020 - 2032
6.8.2.3 Home Care
6.8.2.3.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.8.2.4 Clinic
6.8.2.4.1 Clinic Market Estimates And Forecast, 2020 - 2032
6.8.2.4.2 Physician Office
6.8.2.4.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
6.8.2.4.3 Pharmacy & Retail Clinics
6.8.2.4.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
6.8.2.4.4 Non-Practice Clinics
6.8.2.4.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
6.8.2.4.5 Urgent Care Clinics
6.8.2.4.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
6.8.2.4.6 Others
6.8.2.4.6.1 Others Market Estimates And Forecast, 2020 - 2032
6.9 Others
6.9.1 Others Market Estimates And Forecast, 2020 - 2032
Chapter 7 North America Ivd Market: Segment Analysis, By End-Use, 2020 - 2032 (Volume, Number Of Tests And Instruments)
7.1 North America In Vitro Diagnostic Market: End-Use Movement Analysis
7.2 Hospitals
7.2.1 Hospitals Market Estimates And Forecast, 2020 - 2032
7.3 Laboratories
7.3.1 Laboratories Market Estimates And Forecast, 2020 - 2032
7.4 Home Care
7.4.1 Home Care Market Estimates And Forecast, 2020 - 2032
7.5 Clinic
7.5.1 Clinic Market Estimates And Forecast, 2020 - 2032
7.5.2 Physician Office
7.5.2.1 Physician Office Market Estimates And Forecast, 2020 - 2032
7.5.3 Pharmacy & Retail Clinics
7.5.3.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2020 - 2032
7.5.4 Non-Practice Clinics
7.5.4.1 Non-Practice Clinics Market Estimates And Forecast, 2020 - 2032
7.5.5 Urgent Care Clinics
7.5.5.1 Urgent Care Clinics Market Estimates And Forecast, 2020 - 2032
7.5.6 Others
7.5.6.1 Others Market Estimates And Forecast, 2020 - 2032
Chapter 8 North America Ivd Market: Segment Analysis, By Location, 2020 - 2032
8.1 North America In Vitro Diagnostics Market: Location Movement Analysis
8.2 Point-Of-Care
8.2.1 Poc Market Estimates And Forecast, 2020 - 2032
8.3 Others
8.3.1 Others Market Estimates And Forecast, 2020 - 2032
Chapter 9 North America Ivd Market: Segment Analysis, By Region, 2020 - 2032
9.1 North America
9.1.1 Swot Analysis:
9.1.1.1 North America Ivd Market Estimates And Forecasts, 2020– 2032,
9.1.2 U.S.
9.1.2.1 Key Country Dynamics
9.1.2.2 Risk Factors And Major Chronic Diseases In The U.S.
9.1.2.3 Competitive Scenario
9.1.2.4 Regulatory Framework
9.1.2.5 Reimbursement Scenario
9.1.2.6 U.S. Ivd Market Estimates And Forecasts, 2020 – 2032,
9.1.3 Canada
9.1.3.1 Key Country Dynamics
9.1.3.2 Target Disease Prevalence
9.1.3.3 Competitive Scenario
9.1.3.4 Regulatory Framework
9.1.3.5 Reimbursement Scenario
9.1.3.6 Technological Advancements
9.1.3.7 Canada Ivd Market Estimates And Forecasts, 2020 – 2032,
Chapter 10 Competitive Landscape
10.1 Participant’s Overview
10.2 Financial Performance
10.3 Participant Categorization
10.3.1 Market Leaders
10.3.1.1 North America Ivd Market Share Analysis, 2022
10.3.2 Strategy Mapping
10.3.2.1 Expansion
10.3.2.2 Acquisition
10.3.2.3 Collaborations
10.3.2.4 Product/Service Launch
10.3.2.5 Partnerships
10.3.2.6 Others
10.3.3 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
10.3.4 Innovators
10.3.5 Vendor Landscape
10.3.5.1 List Of Distributors And Channel Partners
10.3.5.2 Key Customers
10.3.6 Public Companies
10.3.6.1 Company Market Position Analysis
10.3.6.2 Competitive Dashboard Analysis
10.3.7 Private Companies
10.3.7.1 List Of Emerging Companies/Technology Disruptors/Innovators
10.3.7.2 Regional Network Map
Chapter 11. Company Profiles
11.1. Abbott
11.2. bioMérieux SA
11.3. Bio-Rad Laboratories, Inc.
11.4. BD
11.5. Siemens Healthcare GmbH
11.6. QIAGEN
11.7. Quidel Corporation
11.8. F. Hoffmann-La Roche Ltd
11.9. Sysmex Corporation
11.10. Charles River Laboratories International, Inc.
11.11. Quest Diagnostics
11.12. Agilent Technologies, Inc.
11.13. Danaher
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers